NASDAQ · BCDA
BioCardia, Inc.
$0.93-$0.02 (-2.26%)
BioCardia, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.56% below the high.
Loading market information…
NASDAQ · LUCY · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Lucyd, Inc’s quoted price sits in the lower half of its reported 52-week range, 58.89% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Lucyd, Inc’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.35. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Lucyd, Inc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Lucyd, Inc develops and sells smart eyewear in North America. It offers smart eyewear products to enable wearer to listen to music, take and make calls, and use voice assistants and ChatGPT to perform smartphone tasks hands-free, as well as prescription eyeglasses, ready-to-wear sunglasses, safety glasses, and sport glasses under the Lucyd Lyte, Lucyd Armor, Nautica, Eddie Bauer, and Reebok brand names. The company also provides Lucyd app for unlimited ChatGPT interactions and tech support. It sells its products through e-commerce and a network of retail stores of resellers. The company was formerly known as Innovative Eyewear, Inc. and changed its name to Lucyd, Inc in October 2025. Lucyd, Inc was founded in 2019 and is headquartered in North Miami, Florida.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 13, 2025 |
| -$0.72+1.37% vs estimate |
| $454.50K-54.55% vs estimate |
| Q4 2024 | Mar 24, 2025 | -$0.41+66.39% vs estimate | $690.69K-1.33% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.99+38.13% vs estimate | $253.60K-71.82% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.93-$0.02 (-2.26%)
BioCardia, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.56% below the high.
$1.86+$0.03 (+1.64%)
Check-Cap Ltd.’s quoted price sits in the upper half of its reported 52-week range, 40.58% below the high.
$1.74-$0.01 (-0.57%)
Biomerica, Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.82% below the high.
$1.76-$0.60 (-25.42%)
Kiora Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.52% below the high.
$3.33+$0.22 (+7.07%)
Sunshine Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.28% below the high.
$0.49-$0.04 (-8.22%)
Aprea Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.87% below the high.
$6.86$0.00 (0.0%)
Meihua International Medical Technologies Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 75.14% below the high.
$0.77+$0.01 (+0.69%)
Profusa, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 99.96% below the high.
